Ranexa may reduce chest pain in patients with type 2 diabetes
According to a study presented at the American College of Cardiology (ACC) meetings in San Francisco and to be published in the Journal of the American College of Cardiology, the drug Ranexa (ranolazine) may be able to reduce chest pain in individuals with type 2 diabetes, especially those with poor blood glucose control. It may even have a secondary benefit: lowering blood sugar levels.
Says lead study author Dr. Mikhail Kosiborod, "Ranolazine is an effect anti-anginal drug in patients with diabetes and may also have a glucose-lowering effect. If the glucose-lowing action of ranolazine is confirmed in future studies, patients with diabetes and angina may derive a dual benefit from this drug."
Gilead Sciences, Inc., the company that makes Ranexa, funded the study.